Prospector Partners LLC Purchases 20,700 Shares of Option Care Health, Inc. $OPCH

Key Points

• Prospector Partners LLC has increased its stake in Option Care Health by 22.9%, now owning approximately 111,200 shares valued at around $3.9 million.
• In the first quarter, other investors such as Versor Investments LP and Raymond James Financial Inc. also significantly increased their holdings in Option Care Health.
• Option Care Health reported a quarterly earnings per share of $0.41, exceeding analysts' expectations, with a revenue of $1.42 billion.

Prospector Partners LLC increased its stake in shares of Option Care Health, Inc. (NASDAQ:OPCH - Free Report) by 22.9% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 111,200 shares of the company's stock after acquiring an additional 20,700 shares during the quarter. Prospector Partners LLC owned about 0.07% of Option Care Health worth $3,886,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Bessemer Group Inc. boosted its stake in Option Care Health by 62.3% during the first quarter. Bessemer Group Inc. now owns 1,560 shares of the company's stock worth $54,000 after buying an additional 599 shares in the last quarter. Public Employees Retirement System of Ohio raised its holdings in shares of Option Care Health by 21.6% in the fourth quarter. Public Employees Retirement System of Ohio now owns 1,870 shares of the company's stock valued at $43,000 after buying an additional 332 shares during the last quarter. Wealthquest Corp bought a new position in shares of Option Care Health in the first quarter valued at about $66,000. Farther Finance Advisors LLC raised its holdings in shares of Option Care Health by 434.8% in the first quarter. Farther Finance Advisors LLC now owns 1,920 shares of the company's stock valued at $67,000 after buying an additional 1,561 shares during the last quarter. Finally, Johnson Financial Group Inc. bought a new position in shares of Option Care Health in the fourth quarter valued at about $47,000. Institutional investors and hedge funds own 98.05% of the company's stock.

Insiders Place Their Bets

In other Option Care Health news, Director Harry M. Jansen Kraemer, Jr. purchased 36,000 shares of the company's stock in a transaction that occurred on Wednesday, August 20th. The shares were acquired at an average price of $27.15 per share, for a total transaction of $977,400.00. Following the purchase, the director owned 375,390 shares in the company, valued at approximately $10,191,838.50. The trade was a 10.61% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Timothy P. Sullivan purchased 20,000 shares of the company's stock in a transaction that occurred on Thursday, August 21st. The stock was acquired at an average price of $27.51 per share, for a total transaction of $550,200.00. Following the purchase, the director owned 49,229 shares in the company, valued at $1,354,289.79. This trade represents a 68.43% increase in their position. The disclosure for this purchase can be found here. 0.64% of the stock is currently owned by corporate insiders.

Option Care Health Stock Up 3.2%

Shares of NASDAQ OPCH traded up $0.90 during trading hours on Friday, hitting $28.74. The company had a trading volume of 2,369,675 shares, compared to its average volume of 1,937,741. The stock has a market capitalization of $4.66 billion, a P/E ratio of 22.99, a price-to-earnings-growth ratio of 1.76 and a beta of 0.79. The company has a quick ratio of 1.00, a current ratio of 1.52 and a debt-to-equity ratio of 0.81. Option Care Health, Inc. has a 1-year low of $21.39 and a 1-year high of $35.53. The firm's 50 day moving average is $29.92 and its 200-day moving average is $31.75.

Option Care Health (NASDAQ:OPCH - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The company reported $0.41 EPS for the quarter, beating the consensus estimate of $0.40 by $0.01. The company had revenue of $1.42 billion during the quarter, compared to the consensus estimate of $1.35 billion. Option Care Health had a return on equity of 17.53% and a net margin of 3.93%.The firm's revenue for the quarter was up 15.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.30 EPS. Option Care Health has set its FY 2025 guidance at 1.650-1.720 EPS. On average, analysts expect that Option Care Health, Inc. will post 1.22 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have weighed in on OPCH shares. JMP Securities boosted their price objective on Option Care Health from $36.00 to $38.00 and gave the stock a "market outperform" rating in a report on Thursday, July 31st. Barrington Research reaffirmed an "outperform" rating and issued a $38.00 price target on shares of Option Care Health in a research note on Thursday, July 10th. Citigroup reaffirmed an "outperform" rating on shares of Option Care Health in a research note on Thursday, July 31st. Finally, UBS Group upgraded Option Care Health from a "neutral" rating to a "buy" rating and boosted their price objective for the company from $38.00 to $40.00 in a research report on Wednesday, April 30th. Eight research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $35.75.

Option Care Health Profile

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.